0000899243-20-020725.txt : 20200730
0000899243-20-020725.hdr.sgml : 20200730
20200730080049
ACCESSION NUMBER: 0000899243-20-020725
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200730
DATE AS OF CHANGE: 20200730
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GADICKE ANSBERT
CENTRAL INDEX KEY: 0001134655
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059270
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P.
CENTRAL INDEX KEY: 0001691428
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059271
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC
CENTRAL INDEX KEY: 0001721035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059272
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management LP
CENTRAL INDEX KEY: 0001687078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059273
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P.
CENTRAL INDEX KEY: 0001721036
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059274
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001134655
GADICKE ANSBERT
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
1
0
1
0
0001691428
UBS Oncology Impact Fund L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
0
1
X*
0001721035
MPM Oncology Impact Management GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
0
1
X*
0001687078
MPM Oncology Impact Management LP
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
0
1
X*
0001721036
Oncology Impact Fund (Cayman) Management L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
0
1
X*
Common Stock
2020-07-28
4
C
0
1269230
A
1269230
I
See Footnote
Common Stock
2020-07-28
4
C
0
84655
A
84655
I
See Footnote
Common Stock
2020-07-28
4
C
0
43687
A
43687
I
See Footnote
Common Stock
2020-07-28
4
C
0
801619
A
801619
I
See Footnote
Common Stock
2020-07-28
4
C
0
42605
A
42605
I
See Footnote
Common Stock
2020-07-28
4
C
0
15820
A
15820
I
See Footnote
Common Stock
2020-07-28
4
C
0
1397574
A
1397574
I
See Footnote
Common Stock
2020-07-28
4
C
0
724702
A
1993932
I
See Footnote
Common Stock
2020-07-28
4
C
0
48336
A
132991
I
See Footnote
Common Stock
2020-07-28
4
C
0
24944
A
68381
I
See Footnote
Common Stock
2020-07-28
4
C
0
457706
A
1259325
I
See Footnote
Common Stock
2020-07-28
4
C
0
24326
A
66931
I
See Footnote
Common Stock
2020-07-28
4
C
0
9033
A
24853
I
See Footnote
Common Stock
2020-07-28
4
C
0
797983
A
2195557
I
See Footnote
Common Stock
2020-07-28
4
P
0
89955
19.00
A
2083887
I
See Footnote
Common Stock
2020-07-28
4
P
0
5994
19.00
A
138985
I
See Footnote
Common Stock
2020-07-28
4
P
0
3096
19.00
A
71727
I
See Footnote
Common Stock
2020-07-28
4
P
0
56814
19.00
A
1316139
I
See Footnote
Common Stock
2020-07-28
4
P
0
3020
19.00
A
69951
I
See Footnote
Common Stock
2020-07-28
4
P
0
1121
19.00
A
25974
I
See Footnote
Common Stock
2020-07-28
4
P
0
160000
19.00
A
2355557
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
3824591
D
Common Stock
1269230
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
255094
D
Common Stock
84655
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
131645
D
Common Stock
43687
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
2415530
D
Common Stock
801619
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
128384
D
Common Stock
42605
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
47674
D
Common Stock
15820
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
4211330
D
Common Stock
1397574
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
2361805
D
Common Stock
724702
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
157529
D
Common Stock
48336
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
81295
D
Common Stock
24944
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
1491666
D
Common Stock
457706
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
79281
D
Common Stock
24326
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
29440
D
Common Stock
9033
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
2600628
D
Common Stock
797983
0
I
See Footnote
Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP ("UBS Oncology") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
On July 28, 2020, MPM Bio Ventures 2014 LP purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
* affiliated funds of Reporting Person
/s/ Ansbert Gadicke, Ansbert Gadicke
2020-07-30
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
2020-07-30
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC
2020-07-30
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP
2020-07-30
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.
2020-07-30